Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FUTURE Study of ctDNA-guided enfortumab vedotin plus pembrolizumab in untreated advanced urothelial carcinoma
2026-527171-28-00Phase 4Authorised
- Sponsor
- Policlinico Gemelli
- Start
- Oct 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of enfortumab vedotin and pembrolizumab in transitional cell carcinoma (TCC) (2 arms), sponsored by Policlinico Gemelli. Primary endpoint: 1-year progression-free survival rate. Planned start Oct 2026; status: authorised.
02
Drugs
enfortumab vedotinpembrolizumab
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on 2026-527171-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-527171-28-00.